Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistBusiness Wire • 11/21/24
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 11/12/24
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/08/24
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/08/24
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 11/06/24
5 Stocks Backed by High Efficiency for Solid Gains Amid VolatilityZacks Investment Research • 11/05/24
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to DeclineZacks Investment Research • 11/01/24
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release TabletsBusiness Wire • 10/21/24
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic DiseasesBusiness Wire • 10/01/24
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's DiseaseBusiness Wire • 09/23/24
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administrationBusiness Wire • 09/05/24
Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain StockZacks Investment Research • 08/21/24
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose VialsBusiness Wire • 08/20/24
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?Zacks Investment Research • 08/09/24
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/09/24